Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 9:5:103-106.
doi: 10.1016/j.ymgmr.2015.11.001. eCollection 2015 Dec.

Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment

Christian J Hendriksz  1 , Joseph Muenzer  2 , Adeline Vanderver  3 , Jonathan M Davis  4 , Barbara K Burton  5   6 , Nancy J Mendelsohn  7   8 , Nan Wang  9 , Luying Pan  9 , Arian Pano  9 , Ann J Barbier  9
Affiliations

Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment

Christian J Hendriksz et al. Mol Genet Metab Rep. .

Abstract

In mucopolysaccharidoses (MPS), glycosaminoglycans (GAG) accumulate in tissues. In MPS II, approximately two-thirds of patients are cognitively impaired. We investigated levels of GAG in cerebrospinal fluid (CSF) in different populations from four clinical studies (including NCT00920647 and NCT01449240). Data indicate that MPS II patients with cognitive impairment have elevated levels of CSF GAG, whereas those with the attenuated phenotype typically have levels falling between those of the cognitively affected patients and healthy controls.

Keywords: Cerebrospinal fluid; Cognitive impairment; Glycosaminoglycans; Idursulfase; Inherited metabolic disease; Lysosomal storage disease; Mucopolysaccharidosis II.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Box plots of total CSF GAG for each subject group. Notes: 1. Surrogate normal data includes data from both the 083 study and biorepository data. 2. Values < 36.7 ng/mL are below the lower limit of quantification. Values < 36.7 ng/mL are replaced with values of 36.7 ng/mL for the plot. CSF, cerebrospinal fluid; GAG, glycosaminoglycan; MPS II, mucopolysaccharidosis II; 045, HGT-HIT-045; 072, HGT-HIT-072; 073, HGT-HIT-073; 083, HGT-HIT-083.
See this image and copyright information in PMC

References

    1. Bach G., Eisenberg F., Jr., Cantz M., Neufeld E.F. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc. Natl. Acad. Sci. U. S. A. 1973;70:2134–2138. - PMC - PubMed
    1. Lawrence R., Brown J.R., Lorey F., Dickson P.I., Crawford B.E., Esko J.D. Glycan-based biomarkers for mucopolysaccharidoses. Mol. Genet. Metab. 2014;111:73–83. - PMC - PubMed
    1. Tomatsu S., Gutierrez M.A., Ishimaru T., Pena O.M., Montano A.M., Maeda H., Velez-Castrillon S., Nishioka T., Fachel A.A., Cooper A., Thornley M., Wraith E., Barrera L.A., Laybauer L.S., Giugliani R., Schwartz I.V., Frenking G.S., Beck M., Kircher S.G., Paschke E., Yamaguchi S., Ullrich K., Isogai K., Suzuki Y., Orii T., Noguchi A. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J. Inherit. Metab. Dis. 2005;28:743–757. - PubMed
    1. Tomatsu S., Okamura K., Maeda H., Taketani T., Castrillon S.V., Gutierrez M.A., Nishioka T., Fachel A.A., Orii K.O., Grubb J.H., Cooper A., Thornley M., Wraith E., Barrera L.A., Laybauer L.S., Giugliani R., Schwartz I.V., Frenking G.S., Beck M., Kircher S.G., Paschke E., Yamaguchi S., Ullrich K., Haskins M., Isogai K., Suzuki Y., Orii T., Kondo N., Creer M., Okuyama T., Tanaka A., Noguchi A. Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J. Inherit. Metab. Dis. 2005;28:187–202. - PubMed
    1. Jones S.A., Parini R., Harmatz P., Giugliani R., Fang J., Mendelsohn N.J. The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS) Mol. Genet. Metab. 2013;109:41–48. - PubMed